DUBLIN, June 17, 2013 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/9rwvs2/north_america) has announced the addition of the "North America Injectable Drug Delivery Market - by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics- Forecasts to 2017" report to their offering.
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self-injection devices.
The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments.
This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Furthermore, due to wide range of applications of injectable drug delivery technologies in varied therapeutic areas, the market is segmented into five categories, namely; auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, Wilson's Disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment).
Key Topics Covered:
2 Executive Summary
3 Market Overview
4 Injectable Drug Delivery Devices Technologies Market
5 Injectable Drug Delivery Formulation Technologies Market
6 Injectable Drug Delivery Technologies Market,By Therapeutic Applications
7 Geographic Analysis
8 Competitive Landscape
9 Company Profiles
- Antares Pharma, Inc.
- Baxter International, Inc.
- Becton, Dickinson And Company
- Eli Lilly And Company
- Hospira, Inc.
- Novo Nordisk A/S
- Unilife Corporation
- West Pharmaceutical Services, Inc.
- Zogenix, Inc.
For more information visit http://www.researchandmarkets.com/research/9rwvs2/north_america
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SOURCE Research and Markets